KR20230024252A - 차폐된 il12 융합 단백질 및 이의 사용 방법 - Google Patents
차폐된 il12 융합 단백질 및 이의 사용 방법 Download PDFInfo
- Publication number
- KR20230024252A KR20230024252A KR1020227036756A KR20227036756A KR20230024252A KR 20230024252 A KR20230024252 A KR 20230024252A KR 1020227036756 A KR1020227036756 A KR 1020227036756A KR 20227036756 A KR20227036756 A KR 20227036756A KR 20230024252 A KR20230024252 A KR 20230024252A
- Authority
- KR
- South Korea
- Prior art keywords
- polypeptide
- masked
- fusion protein
- linker
- fused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993334P | 2020-03-23 | 2020-03-23 | |
| US62/993,334 | 2020-03-23 | ||
| US202163146567P | 2021-02-05 | 2021-02-05 | |
| US63/146,567 | 2021-02-05 | ||
| PCT/CA2021/050383 WO2021189139A1 (en) | 2020-03-23 | 2021-03-23 | Masked il12 fusion proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230024252A true KR20230024252A (ko) | 2023-02-20 |
Family
ID=77890776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227036756A Pending KR20230024252A (ko) | 2020-03-23 | 2021-03-23 | 차폐된 il12 융합 단백질 및 이의 사용 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230122079A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126972A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7773991B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230024252A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115529826A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021240872A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019020A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147126A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011676A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021189139A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200089312A (ko) | 2017-11-28 | 2020-07-24 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| EP3981428A4 (en) | 2019-06-05 | 2023-07-12 | Chugai Seiyaku Kabushiki Kaisha | Protease substrate, and polypeptide including protease cleavage sequence |
| CN115943210A (zh) | 2020-01-20 | 2023-04-07 | 中外制药株式会社 | 配体结合融合蛋白 |
| BR112022019708A2 (pt) * | 2020-04-01 | 2022-12-20 | Xilio Dev Inc | Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CA3178657A1 (en) * | 2020-05-19 | 2021-11-25 | William Winston | Activatable il-12 polypeptides and methods of use thereof |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| US20250051413A1 (en) * | 2021-01-12 | 2025-02-13 | Askgene Pharma Inc. | Chimeric molecules comprising il-12 agonist polypeptide |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| JP2024535925A (ja) * | 2021-09-29 | 2024-10-02 | ザイムワークス ビーシー インコーポレイテッド | 修飾されたインターロイキンp40サブユニットタンパク質及びその使用方法 |
| WO2023141601A1 (en) * | 2022-01-20 | 2023-07-27 | Repertoire Immune Medicines, Inc. | Cd8-targeted il-12 fusion proteins |
| EP4372000B1 (en) * | 2022-02-15 | 2026-06-17 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| CN120035602A (zh) * | 2022-06-17 | 2025-05-23 | 辉瑞公司 | Il-12变体、抗-pd1抗体、融合蛋白及其用途 |
| WO2024148369A1 (en) * | 2023-01-07 | 2024-07-11 | Lyell Immunopharma, Inc. | Targeted il-12 affinity variants |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| AU2024207005A1 (en) * | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2024153768A1 (en) * | 2023-01-20 | 2024-07-25 | Boehringer Ingelheim International Gmbh | Il-12 fc fusion proteins |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥(香港)有限公司 | Klk1融合蛋白質的製備方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| CN119823266A (zh) * | 2023-10-13 | 2025-04-15 | 英脉德医疗科技(广东)有限公司 | 肿瘤微环境特异激活的cd47抗体 |
| CN122349538A (zh) * | 2023-12-07 | 2026-07-07 | 上海药明生物技术有限公司 | 针对il-12受体的异二聚体蛋白 |
| KR20260114559A (ko) * | 2023-12-08 | 2026-07-22 | 아뮤닉스 파마슈티컬스, 인크. | 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법 |
| AU2024407051A1 (en) | 2023-12-18 | 2026-07-30 | Genzyme Corporation | Il-12 loss of potency muteins |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| CN117838836B (zh) * | 2024-01-11 | 2024-06-28 | 广州医科大学附属第二医院 | 白介素39在防治血小板减少症中的应用 |
| WO2025160083A1 (en) * | 2024-01-22 | 2025-07-31 | Onko-Innate Pty Ltd | Targeted low potency il-12 fc fusion proteins and uses thereof |
| WO2025242835A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2026020161A1 (en) * | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| IL300408B2 (en) * | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| EP3436477A2 (en) * | 2016-03-29 | 2019-02-06 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody |
| US10906957B2 (en) * | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| CA3115461A1 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| MX2020014290A (es) * | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| SG11202013248YA (en) * | 2018-07-31 | 2021-02-25 | Amgen Inc | Pharmaceutical formulations of masked antibodies |
| CN113286812B (zh) * | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CA3126707A1 (en) * | 2019-01-29 | 2020-08-06 | Gritstone Bio, Inc. | Multispecific binding proteins |
| WO2021062406A1 (en) * | 2019-09-28 | 2021-04-01 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| CN110777115B (zh) * | 2019-11-21 | 2020-08-21 | 北京启辰生生物科技有限公司 | 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法 |
| KR20230042315A (ko) * | 2020-07-20 | 2023-03-28 | 자임워크스 비씨 인코포레이티드 | 리간드-수용체 쌍 및 생물학적 기능성 단백질을 포함하는 융합 단백질 |
-
2021
- 2021-03-23 MX MX2022011676A patent/MX2022011676A/es unknown
- 2021-03-23 CN CN202180030714.5A patent/CN115529826A/zh active Pending
- 2021-03-23 WO PCT/CA2021/050383 patent/WO2021189139A1/en not_active Ceased
- 2021-03-23 US US17/914,261 patent/US20230122079A1/en active Pending
- 2021-03-23 AU AU2021240872A patent/AU2021240872A1/en active Pending
- 2021-03-23 JP JP2022557752A patent/JP7773991B2/ja active Active
- 2021-03-23 EP EP21776799.5A patent/EP4126972A4/en active Pending
- 2021-03-23 CA CA3147126A patent/CA3147126A1/en active Pending
- 2021-03-23 KR KR1020227036756A patent/KR20230024252A/ko active Pending
- 2021-03-23 BR BR112022019020A patent/BR112022019020A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021189139A1 (en) | 2021-09-30 |
| AU2021240872A1 (en) | 2022-11-17 |
| US20230122079A1 (en) | 2023-04-20 |
| JP7773991B2 (ja) | 2025-11-20 |
| CA3147126A1 (en) | 2021-09-30 |
| CN115529826A (zh) | 2022-12-27 |
| EP4126972A1 (en) | 2023-02-08 |
| EP4126972A4 (en) | 2024-05-01 |
| JP2023518518A (ja) | 2023-05-01 |
| BR112022019020A2 (pt) | 2023-02-07 |
| MX2022011676A (es) | 2023-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7773991B2 (ja) | マスクされたil12融合タンパク質及びその使用方法 | |
| JP7642010B2 (ja) | 改良された抗原結合受容体 | |
| JP7857236B2 (ja) | 免疫活性化Fcドメイン結合分子 | |
| TWI800506B (zh) | 免疫結合物 | |
| US20230227584A1 (en) | Bispecific antibodies comprising a modified c-terminal crossfab fragment | |
| EP3221355B1 (en) | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists | |
| KR20230029621A (ko) | T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법 | |
| CN114127123A (zh) | 结合cea的抗体与4-1bbl的融合 | |
| KR20190135007A (ko) | 종양 항원 제시 유도체 작제물 및 그의 용도 | |
| US20240228567A1 (en) | Modified interleukin p40 subunit proteins and methods of use thereof | |
| KR20210076918A (ko) | 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도 | |
| KR20230047009A (ko) | 암의 치료에 이용하기 위한 세포 상해 유도 치료제 | |
| HK40091599A (en) | Immune activating fc domain binding molecules | |
| HK40085919A (en) | Masked il12 fusion proteins and methods of use thereof | |
| HK40075193A (en) | Bispecific antibodies comprising a modified c-terminal crossfab fragment | |
| RU2825816C2 (ru) | Улучшенные антигенсвязывающие рецепторы | |
| TW202544032A (zh) | Her2特異性抗原結合蛋白與細胞素之偶聯物 | |
| HK40119034A (en) | Interferon gamma variants and antigen binding molecules comprising these | |
| WO2023186756A1 (en) | Interferon gamma variants and antigen binding molecules comprising these |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |